`
`
`
`
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`APOTEX INC.
`Petitioner,
`
`v.
`
`UCB BIOPHARMA SPRL,
`Patent Owner.
`______________
`
`Case IPR2019-00400
`Patent 8,633,194
`______________
`
`
`PATENT OWNER’S REQUEST FOR ORAL ARGUMENT
`UNDER 37 C.F.R. § 42.70(a)
`
`
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`Pursuant to 37 C.F.R. § 42.70(a) and the Board’s October 7, 2020 Revised
`
`
`
`Scheduling Order (Paper 21), Patent Owner UCB Biopharma Sprl (“Patent Owner”)
`
`respectfully requests oral argument in IPR2019-00400, which Patent Owner
`
`understands is currently scheduled for April 22, 2020.
`
`Pursuant to 37 C.F.R. § 42.70(a), Patent Owner respectfully requests up to
`
`thirty (30) minutes of oral argument per side on all issues raised. These issues
`
`include, but are not limited to, the following:
`
`1.
`
`2.
`
`The scope and content of the prior art.
`
`The patentability of claims 1-11 of U.S. Patent No. 8,633,194 in view
`
`of Ground 1: The combination of WO 2004/050094 (“WO ’094”) in
`
`view of the Handbook of Pharmaceutical Excipients, Third Edition
`
`(the “Handbook”) under 35 U.S.C. § 103.
`
`3.
`
`The patentability of claims 1-11 of U.S. Patent No. 8,633,194 in view
`
`of Ground 2: The combination of European Patent Application No.
`
`0605203 A2 (“EP ’203”) in view of the Handbook and U.S. Patent No.
`
`5,698,558 (“the ’558 patent”) under 35 U.S.C. § 103.
`
`4.
`
`5.
`
`The issues raised in Petitioner’s Request for Oral Argument (Paper 39).
`
`Any issues raised by the Petitioner at the oral argument.
`
`1
`
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`Any other issues raised in papers filed in this proceeding, including
`
`
`
`6.
`
`issues to be raised in papers not yet filed or filed concurrently, such as
`
`Motions to Exclude or Strike.
`
`7.
`
`Additional issues on which the Board seeks information or clarification.
`
`Subject to the Board’s approval, Patent Owner intends to use demonstrative
`
`exhibits during the oral argument. Such demonstrative exhibits will be served in due
`
`course according to 37 C.F.R. § 42.70(b). Patent Owner also requests the use of
`
`audio-visual equipment during its presentation, including a computer, projector, and
`
`screen on which to display demonstrative exhibits. Patent Owner does not anticipate
`
`that more than five (5) individuals will attend the argument on its behalf.
`
`
`Dated: March 5, 2020
`
`
`
`
`
`Respectfully submitted,
`
`FENWICK & WEST LLP
`/s/ Robert E. Counihan (electronically
`signed)
`James S. Trainor, Reg. No. 52,297
`Lead Counsel
`
`Robert E. Counihan, Reg. No. 61,382
`Back-Up Counsel
`
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600
`jtrainor@fenwick.com
`rcounihan@fenwick.com
`
`2
`
`
`
`
`
`
`
`
`
`IPR2019-00400
`Patent 8,633,194
`
`
`
`Erica R. Sutter, Reg. No. 77,450
`Back-Up Counsel
`
`FENWICK & WEST LLP
`801 California Street
`Mountain View, CA 94041
`(650) 988-8500
`esutter@fenwick.com
`
`Counsel for Patent Owner UCB Biopharma
`Sprl
`
`
`
`3
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2019-00400
`Patent 8,633,194
`
`
`Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on March 5, 2020, the
`
`foregoing document is being served by filing this document through the Patent Trial
`
`and Appeal Board End to End System, as well as by delivering a copy via electronic
`
`mail upon the following counsel of record for the Petitioner:
`
`jitty.malik@kattenlaw.com
`alissa.pacchioli@kattenlaw.com
`joe.janusz@kattenlaw.com
`lance.soderstrom@kattenlaw.com
`
`
`Date: March 5, 2020
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`/Robert E. Counihan/
`Robert E. Counihan
`Reg. No. 61,382
`Phone: (212) 430-2600
`
`
`
`4
`
`